Butyrate protects against high-fat diet-induced atherosclerosis via up-regulating ABCA1 expression in apolipoprotein E-deficiency mice.
The gut microbial metabolite butyrate is closely linked to the modulation of metabolic disease. However, the efficacy and molecular mechanism of butyrate involved in atherosclerosis remain to be identified. Here, the pharmacological benefits and mechanism of butyrate were investigated in high-fat diet-fed ApoE-/- mice after 16 weeks' administration. Gut microbiota composition was analysed via 16S rRNA gene sequencing of caecal contents. The pharmacological effects of butyrate on atherosclerosis were evaluated in vivo using the ApoE-/- mice model. Serum samples were analysed for physiological parameters, whereas differentially expressed genes in liver samples were identified by hepatic transcriptome profiling. The proteins involved in reverse cholesterol transport were quantified by Western blot and immunohistochemical staining. Finally, the up-regulatory effects of butyrate on ABCA1 were further evaluated in RAW 264.7 cells, and the potential involvement of Sp1 was evaluated by Sp1 inhibition and silencing. Oral gavage of butyrate altered microbiota composition and enhanced gut microbial diversity that decreased by HFD. Butyrate treatment significantly inhibited the HFD-induced atherosclerosis as well as hepatic steatosis without changing body weight gain in ApoE-/- mice. Butyrate showed the metabolic effects in the liver through regulation of gene expression involved in lipid/glucose metabolism. Furthermore, ABCA1 was significantly induced by butyrate in vivo, ex vivo and in vitro, and Sp1 pathway was identified as a potential mechanism. Our results demonstrated that butyrate ameliorates HFD-induced atherosclerosis in ApoE-/- mice via ABCA1-mediated cholesterol efflux in macrophages, which suggesting a promising therapeutic strategy for protecting against atherosclerosis.